Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Latest
Popular

[Vic-]trastuzumab duocarmazine shows improved PFS in pre-treated HER2+ locally advanced or metastatic breast cancer

Dr Cristina Saura - Vall d’Hebron University Hospital, Barcelona, Spain
[Vic-]trastuzumab duocarmazine shows improved PFS in pre-treated HER2+ locally advanced or metastatic breast cancer ( Dr Cristina Saura - Vall d’Hebron University Hospital, Barcelona, Spain )
24 Sep 2021

Drug combination shows promise in treatment-resistant advanced ovarian cancer

Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK
Drug combination shows promise in treatment-resistant advanced ovarian cancer ( Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK )
24 Sep 2021

Challenges in first line ALK+ NSCLC and emerging data on ALK TKIs

Prof Sanjay Popat - The Royal Marsden Hospital, London, UK
Challenges in first line ALK+ NSCLC and emerging data on ALK TKIs ( Prof Sanjay Popat - The Royal Marsden Hospital, London, UK )
23 Sep 2021

Safety of sotorasib and panitumumab in advanced KRAS p.G12C-mutated colorectal cancer

Dr Marwan Fakih - City of Hope Comprehensive Cancer Center, Duarte, USA
Safety of sotorasib and panitumumab in advanced KRAS p.G12C-mutated colorectal cancer ( Dr Marwan Fakih - City of Hope Comprehensive Cancer Center, Duarte, USA )
23 Sep 2021

Welcome to APCCC 2021

Prof Silke Gillessen and Prof Aurelius Omlin
Welcome to APCCC 2021 ( Prof Silke Gillessen and Prof Aurelius Omlin )
23 Sep 2021

IMpower010: A Phase 3 study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC

Dr Enriqueta Felip - Vall d’Hebron University Hospital & Vall d’Hebron Institute of Oncology, Barcelona, Spain
IMpower010: A Phase 3 study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC ( Dr Enriqueta Felip - Vall d’Hebron University Hospital & Vall d’Hebron Institute of Oncology, Barcelona, Spain )
23 Sep 2021

ESMO 2021 Roundup

Dr Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2021 Roundup ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
22 Sep 2021

Melflufen and dexamethasone vs pomalidomide and dexamethasone in relapsed refractory multiple myeloma

Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway
Melflufen and dexamethasone vs pomalidomide and dexamethasone in relapsed refractory multiple myeloma ( Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway )
21 Sep 2021

OncoAlert and ecancer - ESMO 2021 Day 5

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer - ESMO 2021 Day 5 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
21 Sep 2021

Managing patients with EGFR exon 20 ins in NSCLC and EGFR TKI toxicity

Dr Danny Nguyen - City of Hope, Orange County, USA
Managing patients with EGFR exon 20 ins in NSCLC and EGFR TKI toxicity ( Dr Danny Nguyen - City of Hope, Orange County, USA )
21 Sep 2021

PARP inhibitors in prostate cancer: Case based testing and clinical decisions

Dr Neal Shore and Prof Fred Saad
PARP inhibitors in prostate cancer: Case based testing and clinical decisions ( Dr Neal Shore and Prof Fred Saad )
20 Sep 2021

KRYSTAL-1: Adagrasib as monotherapy or combined with cetuximab in patients with CRC harboring a KRASG12C mutation

Dr Jared Weiss - UNC School of Medicine, Chapel Hill, USA
KRYSTAL-1: Adagrasib as monotherapy or combined with cetuximab in patients with CRC harboring a KRASG12C mutation ( Dr Jared Weiss - UNC School of Medicine, Chapel Hill, USA )
20 Sep 2021

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation